Radioisotopes in management of metastatic prostate cancer

about

Radioisotopes in management of metastatic prostate cancer

Item

http://www.wikidata.org/entity/Q28068134

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Radioisotopes in management of metastatic prostate cancer

@ast

Radioisotopes in management of metastatic prostate cancer

@en

Radioisotopes in management of metastatic prostate cancer

@nl

type

Item

label

Radioisotopes in management of metastatic prostate cancer

@ast

Radioisotopes in management of metastatic prostate cancer

@en

Radioisotopes in management of metastatic prostate cancer

@nl

prefLabel

Radioisotopes in management of metastatic prostate cancer

@ast

Radioisotopes in management of metastatic prostate cancer

@en

Radioisotopes in management of metastatic prostate cancer

@nl

P1476

Radioisotopes in management of metastatic prostate cancer

@en

P2093

Amar Raval

http://www.w3.org/2001/XMLSchema#string

Andrew Pridjian

http://www.w3.org/2001/XMLSchema#string

Noelle L Williams

http://www.w3.org/2001/XMLSchema#string

Tu D Dan

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Cancer statistics, 2015

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

P304

277-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3192514

http://www.w3.org/2001/XMLSchema#string

P356

10.4103/0970-1591.189708

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert B. Den

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27843209

http://www.w3.org/2001/XMLSchema#string

P932

5054657

http://www.w3.org/2001/XMLSchema#string